SYC-435 and Infarction--Middle-Cerebral-Artery

SYC-435 has been researched along with Infarction--Middle-Cerebral-Artery* in 1 studies

Other Studies

1 other study(ies) available for SYC-435 and Infarction--Middle-Cerebral-Artery

Article	Year
Development of Novel Journal of medicinal chemistry, 2020, 02-13, Volume: 63, Issue:3 Our previous study had identified ciclopirox (CPX) as a promising lead compound for treatment of ischemic stroke. To find better neuroprotective agents, a series of Topics: Animals; Antioxidants; Apoptosis; Brain; Cell Line, Tumor; Ciclopirox; Drug Design; Humans; Infarction, Middle Cerebral Artery; Male; Molecular Structure; Neuroprotective Agents; Rats, Sprague-Dawley; Structure-Activity Relationship	2020

Article

Year

Journal of medicinal chemistry, 2020, 02-13, Volume: 63, Issue:3

Our previous study had identified ciclopirox (CPX) as a promising lead compound for treatment of ischemic stroke. To find better neuroprotective agents, a series of

Topics: Animals; Antioxidants; Apoptosis; Brain; Cell Line, Tumor; Ciclopirox; Drug Design; Humans; Infarction, Middle Cerebral Artery; Male; Molecular Structure; Neuroprotective Agents; Rats, Sprague-Dawley; Structure-Activity Relationship

2020